GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.
Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.
Investigation reveals tobacco-funded studies appear in top medical journals despite industry bans, as companies invest billions in pharmaceutical subsidiaries.
A large European study found that early-life dog exposure may reduce the genetic risk for atopic eczema, with lab results confirming a biological mechanism involving immune signaling in skin cells.
After showing higher efficacy and a comparable safety profile to Spikevax, the FDA has approved Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk patients.
Nearly one in five children diagnosed with pneumonia in outpatient settings did not receive antibiotics, according to a recent study in JAMA Network Open.